1.9802
price up icon0.00%   0.0002
 
loading
Precedente Chiudi:
$1.98
Aprire:
$1.99
Volume 24 ore:
238.56K
Relative Volume:
0.66
Capitalizzazione di mercato:
$191.93M
Reddito:
$69.56M
Utile/perdita netta:
$-240.05M
Rapporto P/E:
-0.8723
EPS:
-2.27
Flusso di cassa netto:
$-121.90M
1 W Prestazione:
-25.28%
1M Prestazione:
-36.54%
6M Prestazione:
-46.92%
1 anno Prestazione:
+173.48%
Intervallo 1D:
Value
$1.96
$2.035
Intervallo di 1 settimana:
Value
$1.885
$2.70
Portata 52W:
Value
$0.6883
$6.04

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name
Nome
Adc Therapeutics Sa
Name
Telefono
41 21 653 02 00
Name
Indirizzo
BIOPOLE, EPALINGES
Name
Dipendente
274
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
ADCT's Discussions on Twitter

Confronta ADCT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ADCT 1.98 191.93M 69.56M -240.05M -121.90M -2.27
VRTX 450.00 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.66 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 588.46 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.13 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.53 24.89B 3.30B -501.07M 1.03B 11.54

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-08-10 Aggiornamento JP Morgan Underweight → Neutral
2023-04-24 Downgrade BofA Securities Neutral → Underperform
2022-12-06 Iniziato CapitalOne Overweight
2022-11-09 Downgrade BofA Securities Buy → Neutral
2022-09-21 Iniziato JP Morgan Overweight
2022-09-09 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-11-09 Iniziato Wolfe Research Outperform
2021-08-17 Ripresa Jefferies Buy
2021-08-09 Iniziato RBC Capital Mkts Outperform
2021-06-15 Iniziato Cantor Fitzgerald Overweight
2020-12-03 Iniziato Stifel Hold
2020-10-29 Iniziato H.C. Wainwright Buy
2020-06-09 Iniziato BofA/Merrill Buy
2020-06-09 Iniziato Cowen Outperform
Mostra tutto

Adc Therapeutics Sa Borsa (ADCT) Ultime notizie

pulisher
Nov 19, 2024

Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 9.7% - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Head to Head Comparison: ADC Therapeutics (NYSE:ADCT) & Astellas Pharma (OTCMKTS:ALPMY) - Defense World

Nov 18, 2024
pulisher
Nov 16, 2024

Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St

Nov 16, 2024
pulisher
Nov 15, 2024

Redmile Group, LLC Reduces Stake in ADC Therapeutics SA - GuruFocus.com

Nov 15, 2024
pulisher
Nov 13, 2024

ADC Therapeutics shareholders approve capital increase - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Prosight Management, LP Expands Stake in ADC Therapeutics SA - GuruFocus.com

Nov 13, 2024
pulisher
Nov 11, 2024

ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024
pulisher
Nov 11, 2024

ADC Therapeutics : Guggenheim Healthcare Innovation Conference - Marketscreener.com

Nov 11, 2024
pulisher
Nov 11, 2024

Analysts Set ADC Therapeutics SA (NYSE:ADCT) PT at $8.25 - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% UpsideHere's Why - AOL

Nov 08, 2024
pulisher
Nov 08, 2024

ADC Therapeutics SA (NYSE:ADCT) Receives $8.25 Average Price Target from Analysts - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

ADC Therapeutics (NYSE:ADCT) Now Covered by Analysts at Stephens - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Stephens & Co. Initiates Coverage of ADC Therapeutics (ADCT) with Overweight Recommendation - MSN

Nov 08, 2024
pulisher
Nov 07, 2024

ADC Therapeutics SA (ADCT) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

ADC Therapeutics SA Reports Q3 2024: EPS of -$0.42 Misses Estima - GuruFocus.com

Nov 07, 2024
pulisher
Nov 06, 2024

What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings - GuruFocus.com

Nov 06, 2024
pulisher
Nov 05, 2024

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting - The Malaysian Reserve

Nov 05, 2024
pulisher
Nov 05, 2024

ADC Therapeutics' ZYNLONTA Shows 97% Response Rate in Lymphoma Clinical Trials | ADCT Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

ADC Therapeutics to Present at November 2024 Investor Conferences - BioSpace

Nov 05, 2024
pulisher
Nov 04, 2024

ADC Therapeutics to Present at November Investor Conferences - The Malaysian Reserve

Nov 04, 2024
pulisher
Nov 02, 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - The Malaysian Reserve

Nov 02, 2024
pulisher
Nov 01, 2024

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire) - Aktiellt

Nov 01, 2024
pulisher
Nov 01, 2024

ADC Therapeutics (ADCT) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - GlobeNewswire Inc.

Oct 31, 2024
pulisher
Oct 31, 2024

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Malaysian Reserve

Oct 31, 2024
pulisher
Oct 28, 2024

Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT) - Yahoo Finance

Oct 28, 2024
pulisher
Oct 21, 2024

Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 | DelveInsight - The Malaysian Reserve

Oct 21, 2024
pulisher
Oct 21, 2024

Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029 - PR Newswire UK

Oct 21, 2024
pulisher
Oct 21, 2024

The Manufacturers Life Insurance Company Purchases Shares of 26,938 ADC Therapeutics SA (NYSE:ADCT) - Defense World

Oct 21, 2024
pulisher
Oct 15, 2024

ADC Therapeutics SA (NYSE:ADCT) Sees Large Growth in Short Interest - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Adc Therapeutics SA’s Shares Reel: -23.19% Quarterly Revenue Decline Amid 297.81M Market Cap - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

Adc Therapeutics SA (ADCT) rating initates by Cantor Fitzgerald - Knox Daily

Oct 14, 2024
pulisher
Oct 11, 2024

ADC Therapeutics SA's (NYSE:ADCT) institutional investors lost 10% over the past week but have profited from longer-term gains - Simply Wall St

Oct 11, 2024
pulisher
Oct 09, 2024

Antibody Drug Conjugates Industry Report (2024-2032) - GlobeNewswire

Oct 09, 2024
pulisher
Oct 09, 2024

Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 PlayersADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More - 24matins.uk

Oct 09, 2024
pulisher
Oct 01, 2024

ADC Therapeutics : Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 (Form 6-K) - Marketscreener.com

Oct 01, 2024
pulisher
Oct 01, 2024

Antibody Drug Conjugates Market Advancements Highlighted by Research 2024-2033 – Outlook, Overview - WhaTech

Oct 01, 2024
pulisher
Oct 01, 2024

ADC Therapeutics SA (NYSE:ADCT) Shares Bought by XTX Topco Ltd - Defense World

Oct 01, 2024
pulisher
Sep 29, 2024

Rhumbline Advisers Purchases Shares of 85,977 ADC Therapeutics SA (NYSE:ADCT) - Defense World

Sep 29, 2024
pulisher
Sep 28, 2024

Adc Therapeutics (ADCT) Price Target Increased by 9.79% to 8.77 - MSN

Sep 28, 2024

Adc Therapeutics Sa Azioni (ADCT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):